13F filer · CIK 1910264
SR One Capital Management, LP
Redwood City, CA · filing since Q4 2021 · last filing Aug 12, 2026
Reported value
$1.0B
+$123.6M vs prior
Positions
15
New / sold out
3 / 2
Added / reduced
1 / 0
Turnover
21.2%
buys $207.6M · sells $290.5M
Top-10 weight
95.1%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| New | Avalyn Pharma, Inc | +3,308,649 | – | +$108.9M |
| New | Odyssey Therapeutics, Inc. | +3,794,883 | – | +$71.0M |
| New | Mobia Medical, Inc | +1,986,072 | – | +$26.6M |
| Added | ORIC Pharmaceuticals, Inc. | +100,455 | +2.2% | +$1.1M |
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | Arcellx, Inc. | -2,346,630 | -100.0% | $-269.4M |
| Sold out | Oruka Therapeutics, Inc | -430,330 | -100.0% | $-21.1M |
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | Veradermics, Inc.COMMON STOCK | 2,401,868 | $295.3M | 28.42% |
| 2 | Zenas BioPharma, IncCOMMON STOCK | 5,037,854 | $127.9M | 12.31% |
| 3 | CRISPR Therapeutics AGCOMMON SHARES | 2,038,763 | $111.2M | 10.70% |
| 4 | Avalyn Pharma, IncCOMMON STOCK | 3,308,649 | $108.9M | 10.48% |
| 5 | Design Therapeutics, Inc.COMMON STOCK | 6,526,476 | $94.4M | 9.09% |
| 6 | Odyssey Therapeutics, Inc.COMMON STOCK | 3,794,883 | $71.0M | 6.83% |
| 7 | Alumis Inc.COMMON STOCK | 1,959,896 | $55.2M | 5.31% |
| 8 | ORIC Pharmaceuticals, Inc.COMMON STOCK | 4,615,384 | $50.0M | 4.81% |
| 9 | Mineralys Therapeutics Inc.COMMON STOCK | 1,563,966 | $42.2M | 4.06% |
| 10 | ARS Pharmaceuticals, Inc.COMMON STOCK | 4,012,903 | $32.1M | 3.09% |
5 more rows. Subscribe for $29/month to see every row, download the data and use the API.